EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieRandomisierte kontrollierte StudieOpen Access · CC BY-NC-ND 4.0

Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I study

Scott D Newsome, Lawrence Goldstick, Derrick S Robertson, James D Bowen, Robert T Naismith, Ben Townsend, Catarina Figueiredo, Heidemarie Kletzl, Mylene Giraudon, Oscar Bortolami, Dusanka Zecevic, Caroline Giacobino und 4 weitere

Annals of Clinical and Translational Neurology · 2024

DOI: 10.1002/acn3.52229 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Annals of Clinical and Translational Neurology, 2024. Verfasst von Scott D Newsome und 15 weiteren Autor:innen. Beteiligte Einrichtung: Johns Hopkins University School of Medicine, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Immunologic Factors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: F. Hoffmann-La Roche Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Subcutaneous ocrelizumab is being developed to provide treatment flexibility and additional choice to patients with multiple sclerosis. OCARINA I (NCT03972306) is an open‐label, multicenter, Phase 1b, dose‐finding study to investigate the pharmacokinetics, safety, tolerability, and immunogenicity of subcutaneous ocrelizumab and to select a dose for the Phase 3 OCARINA II study (NCT05232825).

Methods

Patients with relapsing or primary progressive multiple sclerosis (aged 18–65 years; Expanded Disability Status Scale score 0.0–6.5) were enrolled into two groups: previously treated with intravenous ocrelizumab (Group A) or naïve to ocrelizumab (Group B). Patients received single ascending doses of subcutaneous ocrelizumab up to 1200 mg. Following dose escalation, new patients in Group A were randomized (1:1) to receive a single 600 mg intravenous ocrelizumab dose or the candidate subcutaneous dose, which was predicted to result in similar exposure as the 600 mg intravenous dose while being safe and well tolerated. The area under the concentration–time curve for both formulations was used to select the subcutaneous ocrelizumab dose. Patients in all cohorts could enter a dose‐continuation phase.

Results

Eighty‐eight and 47 patients were enrolled into Group A and B, respectively; most patients were female (72.7%/63.0%), and mean age at baseline was 45.7 and 39.7 years, respectively. Subcutaneous ocrelizumab was well tolerated across all doses tested. The 920 mg subcutaneous ocrelizumab dose was selected for the OCARINA II study based on pharmacokinetic and safety data.

Interpretation

Subcutaneous ocrelizumab may provide patients with multiple sclerosis with an additional treatment option.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedImmunologic FactorsHumansAdultFemaleMiddle AgedMaleYoung AdultInjections, SubcutaneousMultiple Sclerosis, Relapsing-RemittingMultiple Sclerosis, Chronic ProgressiveAgedAdolescentDose-Response Relationship, DrugMultiple Sclerosis

Substanzen

ocrelizumabAntibodies, Monoclonal, HumanizedImmunologic Factors

Autor:innen und Institutionen

  • Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • University of Cincinnati Waddell Center for Multiple Sclerosis, Cincinnati, Ohio, USA.
  • College of Medicine, University of South Florida, Tampa, Florida, USA.
  • Multiple Sclerosis Center, Swedish Neuroscience Institute, Seattle, Washington, USA.
  • Department of Neurology, Neuroimmunology Section, Washington University, St. Louis, Missouri, USA.
  • F. Hoffmann-La Roche Ltd, Basel, Switzerland.

Förderung

  • F. Hoffmann-La Roche Ltd.

Zitieren

APA

Newsome, S. D., Goldstick, L., Robertson, D. S., Bowen, J. D., Naismith, R. T., Townsend, B., Figueiredo, C., Kletzl, H., Giraudon, M., Bortolami, O., Zecevic, D., Giacobino, C., Clinch, S., Shen, Y. A., Deol-Bhullar, G., & Bermel, R. A. (2024). Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I study. Annals of Clinical and Translational Neurology. https://doi.org/10.1002/acn3.52229

Vancouver

Newsome SD, Goldstick L, Robertson DS, Bowen JD, Naismith RT, Townsend B, et al. Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I study. Annals of Clinical and Translational Neurology. 2024. doi:10.1002/acn3.52229

BibTeX
@article{Newsome2024,
  author = {Newsome, Scott D and Goldstick, Lawrence and Robertson, Derrick S and Bowen, James D and Naismith, Robert T and Townsend, Ben and Figueiredo, Catarina and Kletzl, Heidemarie and Giraudon, Mylene and Bortolami, Oscar and Zecevic, Dusanka and Giacobino, Caroline and Clinch, Susanne and Shen, Yun-An and Deol-Bhullar, Gurpreet and Bermel, Robert A},
  title = {Subcutaneous ocrelizumab in multiple sclerosis: Results of the Phase 1b OCARINA I study},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2024},
  doi = {10.1002/acn3.52229}
}
Kostenlos starten →